Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias

Movement Disorders

Volumn 22, Issue 4, 2007, Pages 533-539

  Paillé, Vincent ^a,b   Henry, Vincent ^a,b   Lescaudron, Laurent ^a,b   Brachet, Philippe ^a,b   Damier, Philippe ^a,c  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CHU de Nantes   (France)

Author keywords

6 OHDA; Akinesia; Dyskinesias; Levodopa; Parkinson's disease; Substantia nigra

Indexed keywords

LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DISEASE SEVERITY; DYSKINESIA; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIPARKINSON AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; DYSKINESIAS; EXTREMITIES; LEVODOPA; MALE; MESENCEPHALON; NERVE DEGENERATION; PARKINSON DISEASE; PROSENCEPHALON; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 34247209582     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21308     Document Type: Article

References (42)

1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925-964.
2. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
3. Damier P, Hirsch EC, Agid Y, et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437-1448.
4. Nutt JG. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2001;8:101-108.
5. Schultz W. MPTP-induced parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology. Gen Pharmacol 1988; 19:153-161.
6. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
7. Bezard E, Ferry S, Mach U, et al. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003;9:762-767.
8. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Sydney: Academic Press; 1982.
9. Olsson M, Nikkhah G, Bentlage C, et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 1995;15:3863-3875.
10. Winkler C, Kirik D, Bjorklund A, et al. L-Dopa-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of Parkinson's Disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2002;10:165-186.
11. Cenci MA, Lee CS, Bjorklund A. L-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 1998;10: 2694-2706.
12. Paille V, Brachet P, Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. Neuroreport 2004;15:561-564.
13. German DC, Manaye KF. Midbrain dopaminergic neurons (nuclei A8, A9, and A10): three-dimensional reconstruction in the rat. J Comp Neurol 1993;331:297-309.
14. Winkler C, Kirik D, Bjorklund A, et al. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog Brain Res 2000;127:233-265.
15. Kirik D, Georgievska B, Bjorklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 2004;7:105-110.
16. Ungerstedt U, Arbuthnott GW. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970;24:485-493.
17. Perese DA, Ulman J, Viola J, et al. A 6-hydroxydopamine-induced selective parkinsonian rat model. Brain Res 1989;494:285-293.
18. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
19. Lane EL, Cheetham SC, Jenner P. Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol 2006;197:284-290.
20. Marin C, Rodriguez-Oroz MC, Obeso JA. Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 2006;197: 269-274.
21. Cousins MS, Salamone JD. Involvement of ventrolateral striatal dopamine in movement initiation and execution: a microdialysis and behavioral investigation. Neuroscience 1996;70:849-859.
22. Lindner MD, Cain CK, Plone MA, et al. Incomplete nigrostriatal dopaminergic cell loss and partial reductions in striatal dopamine produce akinesia, rigidity, tremor and cognitive deficits in middle-aged rats. Behav Brain Res 1999;102:1-16.
23. Lindner MD, Plone MA, Francis JM, et al. Rats with partial striatal dopamine depletions exhibit robust and long-lasting behavioral deficits in a simple fixed-ratio bar-pressing task. Behav Brain Res 1997;86:25-40.
24. Deumens R, Blokland A, Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the Nigrostriatal pathway. Exp Neurol 2002;175:303-317.
25. Ferro MM, Bellissimo MI, Anselmo-Franci JA, et al. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 2005;148:78-87.
26. Betarbet R, Sherer TB, MacKenzie G, et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000;3:1301-1306.
27. Hirsch EC, Hoglinger G, Rousselet E, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. J Neural Transm Suppl 2003:89-100.
28. McNaught KS, Perl DP, Brownell AL, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 2004;56:149-162.
29. McNaught KS, Olanow CW. Proteasome inhibitor-induced model of Parkinson's disease. Ann Neurol 2006;60:243-247.
30. Bove J, Zhou C, Jackson-Lewis V, et al. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006;60:260-264.
31. Kordower JH, Kanaan NM, Chu Y, et al. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 2006;60:264-268.
32. Manning-Bog AB, Reaney SH, Chou VP, et al. Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 2006;60:256-260.
33. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
34. Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 1971;367:49-68.
35. Tetrud JW, Langston JW. MPTP-induced parkinsonism as a model for Parkinson's disease. Acta Neurol Scand Suppl 1989;126:35-40.
36. Lee RG. Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur Neurol 1989;29(Suppl 1):13-18.
37. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(Suppl 3):S3-S12.
38. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
39. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
40. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-dopa-induced dyskinesia. Nat Neurosci 2003;6:501-506.
41. Konradi C, Westin JE, Carta M, et al. Transcriptome analysis in a rat model of L-dopa-induced dyskinesia. Neurobiol Dis 2004;17: 219-236.
42. Papa SM, Engber TM, Kask AM, et al. Motor fluctuations in levodopa treated parkinsonian rats: relation to lesion extent and treatment duration. Brain Res 1994;662:69-74.